Renin-angiotensin-aldosterone system inhibitors improve membrane stability and change gene-expression profiles in dystrophic skeletal muscles. converting enzyme inhibitors (ACEi) and mineralocorticoid receptor (MR) antagonists are FDA-approved drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) and are used to treat heart failure. Combined treatment with the ACEi lisinopril and the nonspecific MR antagonist spironolactone surprisingly improves skeletal muscle, in addition to heart function and pathology in a Duchenne muscular dystrophy (DMD) mouse model. We recently demonstrated that MR is present in all limb and respiratory muscles and functions as a steroid hormone receptor in differentiated normal human skeletal muscle fibers. The goals of the current study were to begin to define cellular and molecular mechanisms mediating the skeletal muscle efficacy of RAAS inhibitor treatment. We also compared molecular changes resulting from RAAS inhibition with those resulting from the current DMD standard-of-care glucocorticoid treatment. Direct assessment of muscle membrane integrity demonstrated improvement in dystrophic mice treated with lisinopril and spironolactone compared with untreated mice. Short-term treatments of dystrophic mice with specific and nonspecific MR antagonists combined with lisinopril led to overlapping gene-expression profiles with beneficial regulation of metabolic processes and decreased inflammatory gene expression. Glucocorticoids increased apoptotic, proteolytic, and chemokine gene expression that was not changed by RAAS inhibitors in dystrophic mice. Microarray data identified potential genes that may underlie RAAS inhibitor treatment efficacy and the side effects of glucocorticoids. Direct effects of RAAS inhibitors on membrane integrity also contribute to improved pathology of dystrophic muscles. Together, these data will inform clinical development of MR antagonists for treating skeletal muscles in DMD.
rently, the standard-of-care treatment for DMD is prednisone, a glucocorticoid that delays loss of ambulation by an average of 2 yr but has numerous serious side effects (6) . Glucocorticoids are widely used to treat both acute and chronic inflammation because of their anti-inflammatory and immunosuppressive effects; however, the underlying mechanism by which these glucocorticoid receptor (GR) agonists benefit skeletal muscles is not fully understood. Several laboratories have demonstrated that prednisone even worsens damage to both skeletal and cardiac muscles in DMD mouse models (13, 14, 31) .
The angiotensin-converting enzyme inhibitor (ACEi) lisinopril and the mineralocorticoid receptor (MR) antagonist spironolactone are FDA-approved drugs with a long history of safety and efficacy in treating heart diseases and have minimal side effects (9, 21) . Lisinopril and spironolactone indirectly and directly, respectively, target the steroid hormone MR through the renin-angiotensin-aldosterone system (RAAS). Lisinopril is now recommended for use in DMD patients starting at the age of 10 yr (19) , and the addition of an MR antagonist has recently been demonstrated to further slow the progression of cardiomyopathy in DMD patients (27) .
Our group has previously shown that combined treatment with lisinopril and spironolactone improved skeletal muscle function and pathology, in addition to the heart, in the utrn ϩ/Ϫ ;mdx ("het") mouse model of DMD (26) . Mice treated with a combination of these drugs showed 80% of normal muscle force generation in both respiratory and limb muscles compared with only 40% of normal force observed in untreated het mice (26) . Treatment also led to a significant reduction in ongoing skeletal muscle damage, but a direct effect on membrane integrity has not been tested.
We recently showed that MRs, not previously investigated in skeletal muscles, were present in limb and respiratory muscles from wild-type and dystrophic mice (8) . The endogenous MR agonist aldosterone was able to induce a large number of gene-expression changes in normal differentiated human myotubes, supporting MR functions as a steroid hormone receptor in skeletal muscles (8) . Together, these data suggest that ACEi and MR antagonists can have a direct therapeutic effect on skeletal muscles.
Inflammation exacerbates muscle damage and contributes to myonecrosis in dystrophic muscles (7) . Previous studies have shown that treatment with anti-inflammatory glucocorticoids can shift macrophages from a proinflammatory M1 phenotype to an anti-inflammatory M2 phenotype and improve muscle pathology (7) . MR has also been shown to regulate macrophage polarization in other tissues but has not been investigated in skeletal muscles (3) . MR activation shifts macrophages to a proinflammatory M1 phenotype, whereas treatment with the nonspecific MR antagonist spironolactone or selective MR antagonist eplerenone promotes an anti-inflammatory M2 phenotype (3) . Together, these data support that MR antagonism can result in anti-inflammatory effects similar to glucocorticoids, which may contribute to the improved muscle pathology observed in lisinopril plus spironolactone (LS)treated dystrophic mice. The goal of this study was to begin to define the cellular and molecular effects of RAAS inhibitors on skeletal muscles. RAAS inhibitors, used in combination clinically in cardiology, were also compared with molecular changes resulting from standard-of-care glucocorticoid treatment.
MATERIALS AND METHODS
Animals. All protocols were approved by the Institutional Animal Care and Use Committee of The Ohio State University, are in compliance with the laws of the United States, and conform to the National Institutes of Health's Guide for the Care and Use of Laboratory Animals. Dystrophin-deficient, utrophin, haplo-insufficient het male mice (38) on a C57BL/10 background were bred in house and used for treated groups or untreated controls. Flexor digitorum brevis (FDB) muscles were used for membrane integrity assays, since they are small, relatively thin muscles that can be dissected cleanly at tendons, allowing for intact surgical removal from the animal, and are typically used for laser-injury experiments in dystrophic mice. Quadriceps muscles were used for the genomic studies, since they are larger muscles that provide sufficient tissue to conduct gene-expression measurements and can be compared with previously published data sets available from this muscle type from various studies on dystrophic mice.
Confocal microscopy membrane integrity assay. Eight 4-wk-old het male mice, housed two per cage, were given water bottles containing 132 mg/l lisinopril (CAS no. 83915-83-7; SBH Medical, Worthington, OH) ϩ 250 mg/l spironolactone (S3378; Sigma-Aldrich, St. Louis, MO; dissolved in 0.1% ethanol) in reverse-osmosis water (n ϭ 4) or reverse-osmosis water only (n ϭ 4), as described in our previous preclinical studies (17, 26) , for 2-4 wk. Medicated water bottles were replaced three times/week, and the volume of water consumed was recorded. Mice were weighed once/week. Mice consumed approximately the predicted dosages of 20 mg·kg Ϫ1 ·day Ϫ1 lisinopril and 37.5 mg· kg Ϫ1 ·day Ϫ1 spironolactone. Membrane integrity assays were performed on isolated FDB muscle bundles to evaluate the effect of LS on treated versus untreated het mice. A group of four C57BL/6J (C57) male mice were used as wild-types for . Fibers for injury experiments were isolated from 4 mice from each group: untreated het, LS-treated het, and C57 wild-type mice. Data are presented as means Ϯ SE. C: quantification of the area under the curve (AUC) among untreated het (U), LS-treated hets, or C57 wild-type mice. One-way ANOVA, followed by Dunnett's post hoc test, was used to identify significance between untreated hets and the 2 other groups. ****P Ͻ 0.0001 compared with untreated hets. comparison with untreated and treated het mice. FDB muscles were surgically isolated and placed in minimal Ca 2ϩ Tyrode solution (140 mM NaCl, 5 mM KCl, 2 mM MgCl 2, and 10 mM HEPES, pH 7.2). Muscle bundles were mechanically separated at the tendon and then adhered on MatTek glass-bottomed Petri dishes using liquid bandage on the exposed tendons (New-Skin). Membrane disruption was induced in the presence of Tyrode supplement with 2.5 M FM 4-64 dye (Thermo Fisher Scientific, Waltham, MA) and 2 mM Ca 2ϩ , with a FluoView FV1000 multi-photon confocal laser-scanning microscope (Olympus, Melville, NY). A circular region of interest was selected along the edge of the sarcolemma and irradiated at 24% of maximum infrared laser power for 3 s. Pre-and postdamage images were captured every 3 s for a total of 60 s. Extent of membrane damage was analyzed using the ImageJ Fiji software (National Institutes of Health, Bethesda, MD) by measuring the fluorescence intensity encompassing the site of damage with results represented as change in fluorescence signal relative to its starting signal (⌬F/F0), as described previously (34) . Fibers for untreated het mice (n ϭ 20), for LS-treated het mice (n ϭ 24), and for C57 mice (n ϭ 16 fibers, bred in house; The Jackson Laboratory, Bar Harbor, ME) were measured from the four mice used for each group. GraphPad Prism (GraphPad Software, La Jolla, CA) was used to fit the ⌬F/F0 curve for each animal, calculate the area under the curve, and perform statistical analysis. The area under the curve represents a quantification of total dye accumulation during the entire period of laser damage. This calculation provides an index of the overall extent of sarcolemmal membrane disruption in each muscle fiber tested. Technical replicates for each biological replicate were averaged. All laser-injury experiments and accompanying analyses were performed by an operator blinded to the treatment groups.
Microarray analysis. Het mice (n ϭ 3/group) were treated from 4 to 6 wk of age with Teklad Rodent Chow (no. 7912), containing 133 mg/kg lisinopril (CAS no. 83915-83-7; SBH Medical) and either 666.66 mg/kg LS (S3378; Sigma-Aldrich) or 2,000 mg/kg eplerenone plus lisinopril (EL; Compound Transfer Program; Pfizer, New York, NY, prepared by Research Diets, New Brunswick, NJ) or water bottles containing 10 mg/l prednisolone (P6004; Sigma-Aldrich; dissolved in 0.04% ethanol) in reverse-osmosis water, replaced three times/week, or left untreated. Chow was used to compare treatment between MR antagonists, since eplerenone is not soluble in water. Mice were weighed weekly, and volume of water or chow consumed was recorded to calculate an average drug dosage of lisinopril (20 mg·kg Ϫ1 ·day Ϫ1 ), spironolactone (100 mg·kg Ϫ1 ·day Ϫ1 ), eplerenone (200 mg·kg Ϫ1 ·day Ϫ1 ), and prednisolone (1.5 mg·kg Ϫ1 ·day Ϫ1 ). All mice were dissected during the middle of the light cycle between 9 AM and 3 PM. One quadriceps muscle from each mouse was removed for RNA processing, and the other quadriceps muscle was embedded in optimal-cutting temperature medium and frozen on liquid nitrogencooled isopentane for histological analyses.
RNA from mouse quadriceps muscles was isolated using TRIzol reagent (Thermo Fisher Scientific), according to the manufacturer's instructions. Samples were DNAse treated using RQ1 DNAse (Promega, Madison, WI) and further purified using the RNeasy mini kit (Qiagen, Germantown, MD) cleanup protocol, and integrity was verified using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). A 100-ng aliquot of total RNA was linearly amplified, and 5.5 g cDNA was labeled and fragmented using the GeneChip WT PLUS Reagent Kit (Affymetrix, Santa Clara, CA), following the manufacturer's instructions. Labeled cDNA targets were hybridized to Affymetrix GeneChip Mouse Transcriptome Array 1.0 for 16 h at 45°C, rotating at 60 rpm. The arrays were washed and stained using the GeneChip Fluidics Station 450 and scanned using the GeneChip Scanner 3000. Arrays were normalized using the gene-level SST RMA algorithm in Expression Console software and comparisons made in Transcriptome Analysis Console software (Affymetrix). The microarray data have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus (accession no. GSE84876). Gene groups were assigned using the Functional Annotation clustering tool from the Database for Annotation, Visualization and Integrated Discovery (DAVID).
Immunofluorescence. Quadriceps muscle cryosections (8 m) were stained with an antibody against mouse IgG (Alexa 488 goat antimouse IgG, 1:200; Thermo Fisher Scientific) to visualize ongoing muscle damage. Samples were mounted using Vectashield mounting medium (Vector Laboratories, Burlingame, CA) with 1 l/ml 4=,6-diamidino-2phenylindole and viewed using an Eclipse E800 microscope (Nikon Instruments, Melville, NY). Images were taken under a ϫ20 objective using a SPOT RT Slider digital camera and SPOT software.
RESULTS
Direct assessment of membrane stability effects of LS treatment on dystrophic skeletal muscles. The results from previous preclinical studies support that treatment with lisinopril plus an MR antagonist reduces ongoing muscle damage, but a direct effect on membrane stability has not been investigated. To confirm the loss of membrane integrity in the het model, FDB muscle bundles from het mice were subjected to laser-induced sarcolemmal membrane damage. An infrared multiphoton laser produced localized damage to the sarcolemmal membrane of intact muscle fibers in the presence of a lipophilic FM4-64 dye, which is nonfluorescent in aqueous solution but fluoresces intensely once it enters the cell. When the membrane re-seals, dye entry ceases, and the fluorescent signal stabilizes. The Fig. 2 . Microarray analysis of 2 wk-treated dystrophic het mice with a nonspecific or specific MR antagonist plus lisinopril results in a comparable number of gene-expression changes. Treatment with lisinopril plus spironolactone (LS) results in decreased expression of 46 genes and increased expression of 20 genes (66 genes total) compared with untreated het. Eplerenone plus lisinopril (EL) treatment results in a comparable number of gene-expression changes, 23 increased and 47 decreased (70 genes total). Thirty-three (50%) of these gene changes are conserved in EL-treated mice compared with untreated het. Treatment with standard-of-care prednisolone (Pred) results in 374 gene-expression changes, 122 increased and 252 decreased compared with untreated het. Only 62 genes of these genes are conserved with LS-or EL-treated mice versus untreated het; 312 genes are specific to prednisolone treatment. Ten gene-expression changes are present in both the LS and EL compared with untreated het but not in the prednisolone group. *Genes that are changed in the opposite directions with MR antagonist and prednisolone treatment. Dbp is represented in both the group of 10 gene changes conserved between LS and EL and as the gene-expression change (*) conserved with prednisolone but in the opposite direction.
tracking of the fluorescence intensity allows resolution of the extent of membrane disruption. Laser-injury assays demonstrated the predicted compromised membrane stability in untreated het mice compared with wild-type controls ( Fig. 1 ). FDB muscles isolated from het mice treated for 4 wk with LS show a significant improvement in membrane integrity compared with untreated het mice (P Ͻ 0.0001; Fig. 1 ).
Treatment with LS or EL results in overlapping geneexpression changes. Whereas increased membrane integrity could underlie some of the improved structure and function observed in dystrophic skeletal muscle following LS treatment, the molecular basis for the efficacy of RAAS inhibition is not clear. We have previously shown gene-expression differences between LS-treated and untreated het mice at the conclusion of a 16-wk study after phenotypes had significantly diverged (8, 26) . These gene-expression differences represent the secondary benefits of treatment, in addition to the potential underlying therapeutic gene-expression changes. We have also shown that the endogenous MR agonist aldosterone can change gene expression in normal human myotubes (8) . Here, we sought to begin to define the molecular changes that may underlie the efficacy of targeting MR in skeletal muscle. We compared treatment with LS, which can also bind glucocorticoid and androgen receptors, with lisinopril, plus the specific MR antagonist EL. These two treatments were recently shown to have equivalent efficacy in het mice (16) .
We performed gene-expression microarray on 6-wk-old male het mice that had been treated for 2 wk with LS or EL or left untreated. These studies also included a group of het mice treated with prednisolone, the active metabolite of prednisone, to begin to differentiate between gene-expression changes that may underlie efficacy versus side effects of standard-of-care glucocorticoids. There were 66 gene-expression changes in quadriceps muscles between LS-treated and untreated het mice ( Fig. 2) . Treatment increased expression of 20 genes (2-to 7-fold) and decreased expression of 46 genes (2-to 7-fold). Similarly, EL treatment led to 70 gene-expression changes compared with untreated-with 23 genes increased (2-to Table 1 Genes were functionally clustered using the Functional Annotation clustering tool from the Database for Annotation, Visualization and Integrated Discovery (DAVID). Positive fold changes indicate that gene expression was increased with treatment and vice versa. The 10 gene-expression changes conserved between LS and EL, but not changed by prednisolone, are shown in bold. 5-fold) and 47 decreased-with 45 of these reduced Ͻ7-fold ( Fig. 2) . S100a8 was decreased 160-fold by EL treatment, which was the largest fold change observed out of any of our previous microarrays. We reanalyzed the raw gene-expression data to determine whether this change was also present with LS treatment. We observed that there was an outlier in the untreated group, and when removed from the analysis, the S100a8 gene was decreased 93-fold in the LS group. In addition, S100a9, which functions as a dimer with S100a8, was now decreased in both EL and LS compared with untreated het mice (64-and 50-fold, respectively).
. Fold changes of gene-expression differences conserved in microarray comparing quadriceps muscles from lisinopril plus spironolactone (LS) and eplerenone plus lisinopril (EL) mice versus untreated het controls (Un)
Thirty-three gene-expression changes were conserved between LS and EL compared with untreated ( Table 1 and Fig.  3A ). Only 10 gene-expression changes conserved between LS and EL compared with untreated were not present or changed in the same direction in the comparison of prednisolone and untreated. Scd1, Scd2, Dbp, Lrtm1, Prkag3, and Nr1d1 were all increased by LS or EL treatment (5.3-, 4.4-, 3.1-, 3.0-, 3.0-, and 2.3-fold, respectively, in EL). Mt1, Pim1, Mt2, and Clu were reduced by LS or EL treatment (2.3-, 2.4-, 2.8-, and 2.9-fold, respectively, in EL). These genes were functionally classified as either ion binding or transcription factors and may underlie MR-specific efficacy.
Short-term prednisolone treatment increases apoptotic genes and damages skeletal muscles. Sixty-two genes were conserved between prednisolone and either LS or EL compared with untreated (Figs. 2 and 3B and Table 2 ). Of these 62 genes, 18 were increased with prednisolone treatment, and 44 were decreased. The highest fold change for increased genes was 3.9-fold, and only two genes were increased Ͼ3-fold. The largest fold change for decreased genes was 42-fold, and 23 of the 44 genes were reduced Ͼ3-fold. Overall, all three drug treatments reduced expression of more genes than they increased. Of the 62 genes conserved between prednisolone and either LS or EL compared with untreated het mice, the majority of genes could be classified into the functional groups of cytokine production/immune response (29%) or regulation of transcription (22.6%; Fig. 3B ). One of the genes conserved among all three groups (Dbp), and three of the genes conserved between LS and prednisolone were changed in the opposite direction with mineralocorticoid antagonists compared with prednisolone ( Fig. 2 and Table 2 ).
Gene-expression changes (312) were present only in the prednisolone versus untreated het comparison and may represent changes associated with either glucocorticoid-specific muscle benefits or side effects (Figs. 2 and 3C and Table 3 ). Staining for IgG in quadriceps muscles of het mice treated for 2 wk and used for this microarray experiment ( Fig. 4 ) recapitulated the increased skeletal muscle damage previously observed after longer treatment with prednisolone (14, 31) . Genes (103) were increased by prednisolone, and 209 were reduced. Increases ranged from 2-to 6.9-fold with 17 gene-expression Fig. 3 . Genes involved in immune response and transcriptional regulation are conserved between MR antagonists and standard-of-care glucocorticoid agonists. A: thirty-three gene-expression changes were conserved between lisinopril plus spironolactone (LS) and eplerenone plus lisinopril (EL). Out of these 33, only 10 were also not conserved with prednisolone treatment. B: there were 62 genes conserved between prednisolone (Pred) and LS or EL treated versus untreated het mice. C: an additional 312 genes were detected only in the Pred versus untreated het group. These genes encompass similar functional groups to those in A and B, including immune response, transcriptional regulators, ion binding, transmembrane, and alternative (Alt.) splicing. However, several functional groups specific to prednisolone treatment were also represented, including 35 genes involved in apoptosis or proteolysis (11.1%), 26 cytokines with chemokine activity (8.3%), 10 cytoskeleton (3.2%), 11 cell migration/motility (3.5%), 4 cell adhesion (1.3%), 3 drug metabolism (Met.; 1%), 3 behavioral response (1%), and 14 genes with GTPase activity (4.5%). D: seventeen gene-expression changes were conserved between Pred and EL, and (E) 21 were conserved between Pred and LS, subsets of the genes represented in B. Protein tyrosine phosphatase, nonreceptor type 1 Ϫ2.1 Ϫ2.4 X changes Ͼ3-fold. Decreased genes were reduced between 2and 57-fold, with 64 genes reduced Ͼ3-fold. Classification of these genes identified several functional groups that were not present in the LS or EL versus untreated het comparison. The functional groups specific to prednisolone treatment were apoptosis or proteolysis (11.1%), cytokine/chemokine activity (8.3%), GTPase activity (4.5%), cytoskeleton (3.2%), cell migration and motility (3.5%), and cell adhesion (1.3%; Fig. 3C ).
Table 2. Fold changes of gene-expression differences in microarray comparing quadriceps muscles from prednisolone (P)-treated and untreated het mice conserved with either lisinopril plus spironolactone (LS) or eplerenone plus lisinopril (EL) versus untreated het controls (Un)

DISCUSSION
To determine whether the improvement in ongoing damage previously observed in dystrophic mice treated with LS was a direct or indirect effect of the drugs on striated muscle fiber sarcolemmal membranes, we carried out a laser-injury membrane-integrity assay. We found that het mice have reduced membrane integrity, as predicted by the loss of dystrophin and reduction of utrophin, similar to that seen in dystrophindeficient mice (34) . LS treatment for Ͻ4 wk is able to restore membrane integrity of muscles isolated from treated het mice to levels not different from that of wild-type mice. These data indicate that this drug treatment can decrease sarcolemmal membrane fragility through direct effects on skeletal muscle fibers or through modification of the muscle ECM. Since muscle bundles were used in these experiments, the native cellular connections to the matrix remain intact, and matrix characteristics could also contribute to improved sarcolemmal membrane integrity.
This increase in membrane integrity could result from multiple mechanisms. Furthermore, there are additional pathways that could contribute to improved muscle structure and function following treatment with LS. We used an unbiased geneexpression analysis approach to establish the effects of LS on the molecular level. Treatment of dystrophic het mice with EL or LS resulted in a comparable number of gene-expression changes (70 and 66, respectively), and~50% of these changes were conserved between the two treatments. There were only 10 gene-expression changes conserved between LS and EL compared with untreated, which were not changed in the same direction by prednisolone compared with untreated.
Not included in this group of 10 genes is S100a8, the highest fold decrease in the EL group (160-fold), which was also not changed by prednisolone but required removal of an outlier to reveal a 93-fold change in LS. S100a8 works as a dimer with S100a9 to form calprotectin, a regulator of immune reactions and inflammatory processes and a marker of neutrophils. Previous studies have shown that infusion of IL-6 cytokine in-creases S100A8 expression in human skeletal muscle (22) . IL-6 expression is also decreased approximately threefold in both LS and EL compared with untreated. Over 50% of geneexpression changes resulting from LS or EL treatment were also conserved in prednisolone-treated mice, and the majority of these genes are functionally classified as either cytokine production/immune response or transcriptional regulators. These data support that MR antagonists likely exhibit antiinflammatory effects similar to prednisolone and that MR and GR may interact with each other both pre-and post-transcriptionally, particularly in inflammatory cells (35, 37) .
Two of the 10 gene-expression changes specific to the LS and EL groups have known associations with altered membrane integrity in dystrophic muscles. Metallothioneins (Mt) 1 and 2, which are decreased by LS and EL treatment, are known to be increased in mdx limb muscles and reduced in mdx mice expressing a therapeutic utrophin transgene (2, 25) . However, a recent study showed that an Mt1 mimetic in a laser-injury assay is protective in a mouse model of limb-girdle muscular dystrophy (1) . Since Mt1 is also regulated by IL-6, different levels of metallothioneins may be protective at different stages of disease.
The remainder of the gene changes conserved between LS and EL, but not prednisolone, have known roles in muscle metabolism. Scd1, which encodes an enzyme essential for skeletal muscle lipid metabolism, showed the highest fold increase with treatment. The increase of Scd1 expression in skeletal muscle can enhance muscle triglyceride synthesis, glucose uptake, and exercise capacity (28) . Diminished Scd1 activity can lead to increased levels of saturated fatty acids that result in inflammation, lipotoxicity, and insulin resistance (28) .
Nr1d1 encodes the rev-ERB␣ nuclear receptor expressed in oxidative muscle and is known to increase exercise capacity (36) . Pim1 encodes a serine/threonine kinase that regulates metabolism and is associated with high intramuscular fat in beef, and knockout of Clu, encoding clusterin in mice, is protective against a high-fat diet (15, 30) . Prkag3 encodes the regulatory subunit of AMP kinase, which is known to play a major role in muscle metabolism and also to regulate the muscle circadian clock (33) . Dbp, decreased by prednisolone and in muscle atrophy but increased by both LS and EL treatment, and Per3, increased in LS only, are circadian clockcontrolled genes in muscle (24, 33) . Clock genes have recently been shown to play an important purpose in normal muscle function and metabolism (12) . These metabolic gene-expression changes may underlie the improved recovery from fatigue observed in diaphragm and extensor digitorum longus muscles Tumor necrosis factor-␣-induced protein 6 Ϫ5.5 Ϫ7 X
Genes were functionally clustered using the Functional Annotation clustering tool from the Database for Annotation, Visualization and Integrated Discovery (DAVID). Positive fold changes indicate gene expression was increased with treatment and vice versa. Bold X's represent a lack of a 2-fold gene-expression change in the LS or EL treatment groups. Values underlined and italicized highlight gene-expression changes going in the opposite direction with P versus LS or EL treatment. *Functionally conserved gene family members in LS or EL comparisons (Cited4, Casp4, and Asb15). Table 3 Tripartite motif-containing 25 Ϫ2.4
. Fold changes of gene-expression differences specific to microarray comparing quadriceps muscles from prednisolone (Pred)-treated het mice versus untreated het controls (Un)
Cytokines with chemokine activity
Adamts9 A disintegrin-like and metallopeptidase (reprolysin-type) with thrombospondin type 1 motif, 9
Ϫ5.0 Ccl8
Chemokine
Chemokine (C-X-C motif) ligand 9
Ϫ8.0 Cxcl13
Chemokine (C-X-C motif) ligand 13 6.9 Cxcr4
Chemokine (C-X-C motif) receptor 4 Ϫ2.9 Egf Epidermal growth factor 2.1 Entpd1
Ectonucleoside triphosphate diphosphohydrolase 1
Ϫ2.1 Hck
Hemopoietic cell kinase Ϫ2.0 Hif1a
Hypoxia-inducible factor 1, alpha subunit Ϫ3.7
Igfbp3
Insulin-like growth factor-binding protein 3 2.7
Igh-VJ558
Immunoglobulin heavy chain (J558 family) 2. Guanylate-binding protein 2
Ϫ2.2 Gbp3
Guanylate-binding protein 3
Ϫ2.3 Gbp7
Guanylate-binding protein 7 Ϫ2.3 Gbp8
Guanylate-binding protein 8
Ϫ2.3 Gbp9
Guanylate-binding protein 9 Ϫ2.7 Gbp10
Guanylate-binding protein 10 Ϫ2.9 Gbp11
Guanylate-binding protein 11 Ϫ2.1 Gm12185
Predicted gene 12185 Ϫ2.5 Gvin1
GTPase, very large interferon-inducible 1
Rap guanine nucleotide-exchange factor (GEF) 5 Ϫ2.9
Rgs5
Regulator of G-protein signaling 5 Ϫ2.7 Tgtp2
T Cell-specific GTPase 2 Ϫ3.2
Apoptosis and proteolysis/regulation of apoptosis
Agt Angiotensinogen (serpin peptidase inhibitor, clade A, member 8)
Aldh1a1
Aldehyde dehydrogenase family 1, subfamily A1 5.9 Asb2
Ankyrin repeat and SOCS box-containing 2 2.3 Asb11
Ankyrin repeat and SOCS box-containing 11 2.2 Asb12
Ankyrin repeat and SOCS box-containing 12 2.1 Atp1a2
ATPase, Na ϩ /K ϩ transporting, alpha 2 polypeptide 2. This list excludes the gene-expression changes also conserved with either LS or EL treatment, listed in Table 2 . Genes were functionally clustered using the Functional Annotation clustering tool from the Database for Annotation, Visualization and Integrated Discovery (DAVID). Positive fold changes indicate that gene expression was increased with treatment and vice versa. Fig. 4 . Short-term prednisolone treatment worsens ongoing muscle damage in dystrophic het mice. Immunofluorescence staining for serum IgG on representative quadriceps (Quad) sections from het mice treated for 2 wk with LS, EL, or prednisolone (Pred) and used for microarray analysis. Mice treated with 1.5 mg·kg Ϫ1 ·day Ϫ1 prednisolone (n ϭ 3) had more ongoing damage than LS-treated (n ϭ 3), EL-treated (n ϭ 3), and untreated het mice (n ϭ 3). from LS-and EL-treated mice, although the contribution of each gene product will require further investigation.
Two gene-expression changes were conserved between the het mice treated with LS or EL for 2 wk and mice treated for 16 wk with LS from our previous study compared with untreated hets (8) . Cited4, which was decreased by 2-wk EL and 16-wk LS treatment, encodes a cAMP response elementbinding protein-binding protein/p300 transcriptional coactivator-binding protein that has not been directly investigated in skeletal muscle. However, Cited4 was increased in exercisedinduced cardiac hypertrophy and controls myocyte elongation and proliferation (4, 29) . Adamst1, decreased by 2-and 16-wk LS treatment, EL treatment, and prednisolone treatment, is an anti-angiogenic regulator transiently increased during myotube maturation. Adamst1 is known to be drastically reduced in skeletal muscle by exercise and predicted to be involved in ECM remodeling (18) .
There were 312 gene-expression changes present only in the prednisolone versus untreated het comparison. Functional groups specific to prednisolone treatment include genes involved in apoptosis or proteolysis, cytokines with chemokine activity, GTPase activity, cell migration and motility, cell adhesion, and cytoskeleton. Almost all apoptotic and proteolytic genes are increased with prednisolone treatment, whereas genes that negatively regulate apoptosis are all decreased. GR-induced increases in proapoptotic gene expression are seen in other tissues, including skin, bone, and neurons (5, 10, 23) . The reduction of genes involved in cell motility and migration by prednisolone could contribute to impaired regeneration and explain the increased muscle damage associated with prednisolone treatment in animal models of DMD (11) . Treatment with prednisolone also decreased expression of GTPase genes, including several members of the Gbp family that are induced by IFN-␥ and play a key role in protective immunity (32) .
This study has demonstrated that short-term treatment with LS is able to restore membrane integrity of isolated dystrophic mouse muscles and decrease inflammatory genes. The combination of these effects could contribute to the cell and molecular mechanisms that lead to the improved muscle structure and function in dystrophic muscle following treatment with LS. Microarray analysis identified several potential gene targets that may specifically underlie the efficacy of RAAS inhibitors on dystrophic muscles, while also identifying geneexpression changes that may contribute to the side effects of prednisolone on skeletal muscles. This information may be used to develop biomarkers to monitor RAAS inhibitor or glucocorticoid agonist treatment, develop a temporally coordinated treatment with both drug classes, or identify novel therapeutics with these more-specific treatment targets.
